Online inquiry

IVTScrip™ mRNA-Anti-LYPD3, BAY 1112623(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3568MR)

This product GTTS-WQ3568MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets LYPD3 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_014400.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 27076
UniProt ID O95274
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LYPD3, BAY 1112623(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3568MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3793MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ10127MR IVTScrip™ mRNA-Anti-LAG3, LAG-525(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LAG-525
GTTS-WQ12132MR IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MORAb-004
GTTS-WQ12527MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA NPVPDR001
GTTS-WQ13835MR IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-1193
GTTS-WQ9484MR IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA IPH-5401
GTTS-WQ12235MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ8933MR IVTScrip™ mRNA-Anti-IL1B, IL-1 Trap(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA IL-1 Trap
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW